Rapamycin‑Induced Mitochondrial Autophagy Drives Demethylation of a 10‑CpG Mortality Signature to Lower Human Mortality Risk

Mira Stănescu· Mar 23, 2026

Mechanism: Rapamycin inhibits mTORC1, boosting mitophagy and sparing NAD+ to activate SIRT1 and TET enzymes, which demethylate the 10-CpG mortality score. Readout: Readout: The 10-CpG score is reduced by ≥15%, correlating with a ≥30% lower hazard for all-cause mortality, cardiovascular disease, and cancer.

Hypothesis

Rapamycin extends lifespan in mice by inhibiting mTORC1 and boosting autophagy. In humans, short‑term rapamycin improves lean mass and pain but mortality data are lacking [1]. We propose that the longevity benefit of rapamycin depends on its ability to remodel a specific epigenetic mortality signature—the 10‑CpG mortality score that predicts all‑cause, cardiovascular and cancer death better than GrimAge or PhenoAge [5]. Rapamycin‑induced mitophagy reduces mitochondrial ROS, which lowers NAD+ consumption and activates SIRT1‑driven TET enzyme activity. This cascade demethylates the 10‑CpG sites located in promoters of NF‑κB‑regulated inflammatory genes, thereby decreasing the mortality score and translating into lower hard‑endpoint incidence.

Mechanistic Reasoning

mTORC1 inhibition → ↑ autophagosome formation → selective mitochondrial autophagy (mitophagy) → ↓ mitochondrial ROS.
Reduced ROS spares NAD+ for SIRT1 deacetylase activity.
Active SIRT1 deacetylates and stimulates TET2/TET3 dioxygenases.
TET enzymes oxidize 5‑mC to 5‑hmC, initiating demethylation at CpG islands of inflammatory gene promoters (e.g., IL6, TNF).
Demethylation of the 10‑CpG mortality score lowers the epigenetic predictor of mortality.
Lower score reflects a biological state less prone to age‑related disease, thus decreasing mortality risk.

Testable Prediction

A double‑blind, placebo‑controlled trial in adults aged 45‑65 will randomize participants to low‑dose rapamycin (1 mg weekly) plus time‑restricted eating (10‑hour window) versus placebo for 24 months. Primary outcome: change in the 10‑CpG mortality score at 12 mo and 24 mo. Secondary hard endpoints: all‑cause mortality, incident cardiovascular disease, and cancer diagnoses. We hypothesize that the rapamycin + intervention arm will show a ≥15 % reduction in the 10‑CpG score relative to placebo and that this reduction mediates a ≥30 % lower hazard for hard endpoints over the trial period.

Falsifiability

If rapamycin + time‑restricted eating fails to produce a significant change in the 10‑CpG score, or if score change does not correlate with reduced hard‑endpoint incidence, the hypothesis is refuted. Additionally, if demethylation of the 10‑CpG sites is not observed despite mTOR inhibition (measured by p‑S6K suppression), the proposed mechanistic chain is invalidated.

Broader Implications

Linking a mechanistic epigenetic biomarker to mortality outcomes would shift the field from surrogate marker chasing to causally validated aging interventions. Positive results would justify larger, longer trials powered for mortality and provide a molecular read‑out for dose optimization. Negative results would underscore that mTOR‑dependent autophagy alone is insufficient to remodel the epigenetic mortality clock in humans, prompting focus on complementary pathways (e.g., NAD+ boosters, senolytics).

References

Hypothesis

Mechanistic Reasoning

mTORC1 inhibition → ↑ autophagosome formation → selective mitochondrial autophagy (mitophagy) → ↓ mitochondrial ROS.

Reduced ROS spares NAD+ for SIRT1 deacetylase activity.

Active SIRT1 deacetylates and stimulates TET2/TET3 dioxygenases.

TET enzymes oxidize 5‑mC to 5‑hmC, initiating demethylation at CpG islands of inflammatory gene promoters (e.g., IL6, TNF).

Demethylation of the 10‑CpG mortality score lowers the epigenetic predictor of mortality.

Lower score reflects a biological state less prone to age‑related disease, thus decreasing mortality risk.

Testable Prediction

Falsifiability

Broader Implications